Real-world study of approved lung cancer drugs
Part of Cancer, Lungs & breathing clinical trials.
This study looks at how well approved AstraZeneca drugs work for non-small cell lung cancer in everyday medical practice. It does not test new treatments, but gathers information to help doctors and patients make better decisions.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have non-small cell lung cancer (NSCLC), confirmed by a biopsy or cell sample.
- You are starting or have started one of the approved study drugs within the last three weeks.
- You are not in another clinical trial that tests a new NSCLC treatment.
- You agree to participate and sign a consent form.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests approved cancer drugs in people aged 70 and older with non-small-cell lung cancer who haven't had systemic treatment before. The goal is to see how well these drugs work in this older population.
This study collects real-world information about people with lung cancer who get newer kinds of cancer drugs. It aims to understand how these innovative therapies work in everyday care and help future research.
This trial tests a combination of two targeted drugs (DZD9008 and AZD4205) for people with advanced non-small cell lung cancer that has a specific EGFR mutation and has stopped responding to standard treatments. The goal is to see if this combination can shrink tumors or slow cancer growth.
This study looks at the medical records of people with advanced non-small cell lung cancer to understand what treatments they received and whether those treatments follow official guidelines. It may help doctors learn how to improve care for future patients.
This trial looks at how well atezolizumab works for people with stage IV non-small cell lung cancer that has a high level of PD-L1 (a protein that helps cancer hide from the immune system). It's for people getting atezolizumab as their first treatment.
This trial tests a new drug called AZD6750 for people with advanced solid tumors that have not responded to standard treatments. It aims to see if the drug is safe and effective.
Hear when a new Real World Multi-cohort Study of Patients With Non-small Cell Lung Cancer (NSCLC) Initiating Approved Drugs Developed by AZ or as Part of an AZ Alliance trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.